OSR Holdings & SillaJen Collabs to Develop New Therapies for US Market Extension

OSR Holdings and SillaJen Collaborate to Develop New Therapies and Expand into the U.S. Market

Overview

OSR Holdings, a significant global healthcare holding company, has recently announced the signing of a memorandum of understanding (MOU) with SillaJen, a biotech firm listed on Kosdaq and renowned for its pipeline of immuno-oncology drug candidates. This MOU signifies a commitment to mutual technological sharing and leveraging clinical development resources, initiating a strategic partnership between the two entities. The collaboration aims to explore synergies between their existing platform technologies and novel drug candidates.

OSR Holdings: 

• Established in 2019 in South Korea, OSR Holdings operates on a ""hub-and-spoke"" business model, a trend increasingly observed in the biopharmaceutical sector over the past decade. 
• This model allows for centralized management of drug development strategies, clinical plans, and resource allocation by the holding company. 
• Subsidiaries under this model focus on advancing new drug assets and technological innovations, enhancing scalability and resource efficiency, particularly during the clinical phases of drug development.

OSR Holdings' Portfolio

• OSR Holdings' portfolio includes Vaximm AG, a Swiss entity specializing in immuno-oncology therapeutics; Darnatein, a South Korean company developing osteoarthritis therapeutics; and RMC, a distributor of specialized medical devices. 
• Notably, Vaximm AG has completed Phase 2a clinical trials for glioblastoma, while Darnatein, founded by Dr. Seung-Hyun Choi, is known for its robust platform for cartilage and bone regeneration, with ongoing development of new drugs for various disease indications.

SillaJen

• SillaJen possesses a diverse pipeline of new drugs, such as the SJ-600 series and BAL0891, and is at the forefront of developing anti-cancer viruses based on its GEEV® platform. 
• GEEV® is recognized for its immune-evasion capabilities, allowing anti-cancer viruses to efficiently target affected areas. 
• The SJ-600 series is built upon this platform, while BAL0891, a mitotic checkpoint inhibitor, has progressed to Phase 1 clinical trials targeting solid tumors in the United States.

Sung Jae "Alex" Yu, COO of OSR Holdings, expressed enthusiasm about the MOU, stating that it marks the transition of the two companies into strategic partners in the global immuno-oncology market. He anticipates exploring various opportunities to strengthen the relationship and collaborations, particularly in the U.S., the largest pharmaceutical market worldwide.

A representative of SillaJen echoed this sentiment, anticipating synergies from the collaboration between their original anti-cancer drug development technology and OSR Holdings' global business expertise. They highlighted the opportunity to showcase SillaJen's pipeline in the U.S. market, alongside existing partnerships.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!